IN8bio, Inc.
NASDAQ:INAB
Overview | Financials
Company Name | IN8bio, Inc. |
Symbol | INAB |
Currency | USD |
Price | 0.27 |
Market Cap | 19,570,464 |
Dividend Yield | 0% |
52-week-range | 0.217 - 1.93 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Tai-Wei Ho |
Website | https://in8bio.com |
An error occurred while fetching data.
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD